You can do it now or later - now will be easier

Think of the challenges confronted by the health system and makers of the early CAR-Ts - Novartis and Gilead. Australia will already struggle to treat the few hundred people currently lucky enough to qualify for funded access to approved CAR-T therapy. Now extrapolate that to ten gene and cell-based therapies in a single year. …